<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>2691</number>
    <updateDate>2023-01-11T13:39:41Z</updateDate>
    <updateDateIncludingText>2023-01-11T13:39:41Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2018-04-17</introducedDate>
    <congress>115</congress>
    <committees>
      <item>
        <systemCode>ssfi00</systemCode>
        <name>Finance Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2018-04-17T20:26:08Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Opioid Crisis Accountability Act of 2018</title>
        <congress>115</congress>
        <number>5782</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2018-05-31</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2018-04-17</actionDate>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Finance.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2018-04-17</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>S000033</bioguideId>
        <fullName>Sen. Sanders, Bernard [I-VT]</fullName>
        <firstName>Bernard</firstName>
        <lastName>Sanders</lastName>
        <party>I</party>
        <state>VT</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>H001075</bioguideId>
        <fullName>Sen. Harris, Kamala D. [D-CA]</fullName>
        <firstName>Kamala</firstName>
        <lastName>Harris</lastName>
        <party>D</party>
        <state>CA</state>
        <middleName>D.</middleName>
        <sponsorshipDate>2018-04-17</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>G000555</bioguideId>
        <fullName>Sen. Gillibrand, Kirsten E. [D-NY]</fullName>
        <firstName>Kirsten</firstName>
        <lastName>Gillibrand</lastName>
        <party>D</party>
        <state>NY</state>
        <middleName>E.</middleName>
        <sponsorshipDate>2018-04-19</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>B001277</bioguideId>
        <fullName>Sen. Blumenthal, Richard [D-CT]</fullName>
        <firstName>Richard</firstName>
        <lastName>Blumenthal</lastName>
        <party>D</party>
        <state>CT</state>
        <sponsorshipDate>2018-04-19</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Business ethics</name>
        </item>
        <item>
          <name>Business expenses</name>
        </item>
        <item>
          <name>Business records</name>
        </item>
        <item>
          <name>Child health</name>
        </item>
        <item>
          <name>Civil actions and liability</name>
        </item>
        <item>
          <name>Corporate finance and management</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Department of Justice</name>
        </item>
        <item>
          <name>Department of Labor</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Drug trafficking and controlled substances</name>
        </item>
        <item>
          <name>Drug, alcohol, tobacco use</name>
        </item>
        <item>
          <name>Education programs funding</name>
        </item>
        <item>
          <name>Elementary and secondary education</name>
        </item>
        <item>
          <name>Employment taxes</name>
        </item>
        <item>
          <name>Executive agency funding and structure</name>
        </item>
        <item>
          <name>Government information and archives</name>
        </item>
        <item>
          <name>Government studies and investigations</name>
        </item>
        <item>
          <name>Government trust funds</name>
        </item>
        <item>
          <name>Health programs administration and funding</name>
        </item>
        <item>
          <name>Health promotion and preventive care</name>
        </item>
        <item>
          <name>Income tax credits</name>
        </item>
        <item>
          <name>Marketing and advertising</name>
        </item>
        <item>
          <name>Medical research</name>
        </item>
        <item>
          <name>Preschool education</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
        <item>
          <name>Research and development</name>
        </item>
        <item>
          <name>Securities</name>
        </item>
        <item>
          <name>Small business</name>
        </item>
        <item>
          <name>Wages and earnings</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2018-04-17</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2019-06-20T19:27:10Z</updateDate>
        <text><![CDATA[ <p><b>Opioid Crisis Accountability Act of 2018</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks.</p> <p>The bill penalizes drug manufacturers or distributors who illegally advertise, market or distribute an opioid product, including by (1) imposing a civil fine or salary confiscation, (2)revoking any remaining period of market exclusivity for such product, (3)requiring reimbursement of federal funding received for such product, and (4)prohibiting certain tax credits.</p>]]></text>
      </summary>
    </summaries>
    <title>Opioid Crisis Accountability Act of 2018</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Opioid Crisis Accountability Act of 2018</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic in the United States.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Opioid Crisis Accountability Act of 2018</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2018-04-17T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-115s2691is/xml/BILLS-115s2691is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2018-04-17</actionDate>
      <text>Read twice and referred to the Committee on Finance.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
